



MEDICATION REGISTRATION

Check out the new generics approved for commercialization in Brazil

Among the new products are new therapeutic options for patients with HIV and hypertension.

By: Ascom / Anvisa

Posted: 04/23/2018 15:05

Last Modified: 04/23/2018 15:12

[Compartilhar 0](#)[Tweeter](#)[G+ Compartilhar](#)

The National Agency of Sanitary Surveillance (Anvisa) has just granted the guarantee for the commercialization of four (4) generic medicines unpublished in Brazil. One of them is Entricitabine combined with Tenofovir Fumarate Desoproxil, a product that will be part of the therapeutic arsenal used to treat people living with HIV. The reference product is Truvada, which includes pre-exposure prophylaxis (PrEP) used to reduce the risk of sexually acquired infection in high-risk adults. In Brazil, the holder of the registration is Blanver Farmoquímica e Farmacêutica S / A.

Another new generic product with registration approved by Anvisa is Perindopril Erbumine combined with Indapamide, indicated for the treatment of arterial hypertension, also known as high blood pressure. According to the Brazilian Society of Hypertension (SBH), this disease is very common, affecting one in four adults. In this case, the company holding the registration in the country is EMS S / A.

Among the products approved by Anvisa is also the unprecedented generic Bilastine, indicated for the symptomatic treatment of allergic rhinoconjunctivitis (intermittent or persistent) and urticaria. The company that holds the registration is EMS S / A.

Completing the list of the four unpublished generic drugs approved by Anvisa is Testosterone Undecylate. This product will be used in sex hormone replacement therapies in men who have primary and secondary hypogonadism. The holder of the registration of this medicine in Brazil is Eurofarma Laboratório S / A.

The approval of these records was published on Monday (23), in the Official Gazette (DOU) (<http://pesquisa.in.gov.br/imprensa/jsp/visualiza/index.jsp?jornal=531&pagina=10&data=23/04/2018>).

Affordable price

For Anvisa, the incorporation of new generics is important because it expands patients' access to medicines at a more affordable cost. Under Brazilian law, this type of product must be made available on the market at a discount of at least 35% in relation to the maximum Anvisa table price.

It is important to note that the generic product is sold in the national market. In 2016 alone, 1.46 billion generic packs were marketed in Brazil. This amount represented 32.4% of all sales made in the year, according to information from the second edition of the Statistical Yearbook of the Pharmaceutical Market 2016, launched by Anvisa in 2017.

Want to know Anvisa news first hand? Follow us on Twitter [@anvisa_oficial](https://twitter.com/anvisa_oficial) (https://twitter.com/anvisa_oficial) and Facebook [@AnvisaOficial](https://www.facebook.com/AnvisaOficial/) (<https://www.facebook.com/AnvisaOficial/>)

Did you find any information wrong or outdated? [click here](#)

generic (http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=gen%C3%A9ricos) drug registration (http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=registro+de+medicamentos)

Back to top!

 (<https://www.facebook.com/AnvisaOficial/>)

 (<http://www.youtube.com/user/anvisaoficial>)

 (<https://twitter.com/audiovisualanvisa>)

Barra GovBr (<http://www.acessoainformacao.gov.br/>) (<http://www.brasil.gov.br/>)